Status:
COMPLETED
Safety and Feasibility of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension
Lead Sponsor:
Zhejiang University
Conditions:
Idiopathic Pulmonary Arterial Hypertension
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Recent researches indicate that impairment of vascular and endothelial homeostasis plays a major role in the initiation and development of IPAH.We have recently reported the safety and feasibility dat...
Eligibility Criteria
Inclusion
- The inclusion criteria included a base-line six minute walking distance between 100 and 450 m
- A resting mean pulmonary-artery pressure greater than 30 mm Hg
- A pulmonarycapillary wedge pressure of less than 15 mm Hg
- Pulmonary vascular resistance greater than 240 dyn•sec•cm-5
- 18-60 years old
Exclusion
- The exclusion criteria included secondary pulmonary hypertension as a result of heart disease
- Pulmonary disease
- Sleep-associated disorders
- Chronic thromboembolic disease
- Autoimmune or collagen vascular disease
- HIV infection
- Liver disease
- New York Heart Association functional class IV
- Major bleeding requiring blood transfusion
- Diabetes
- Renal dysfunction
- Evidence for malignant diseases were excluded
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT00641836
Start Date
July 1 2005
End Date
December 1 2007
Last Update
March 24 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Cardiology, the First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310003